Aytu BioScience closes on $5.175M note financing

Aytu BioScience closes on $5.175M note financing

ENGLEWOOD-- Aytu BioScience Inc . (OTCQB: AYTU), a specialty health care company focused on developing treatments for urological and related conditions, announced it has closed on the final... Read More

Thursday September 3, 2015 0 comments Tags: Englewood, Aytu BioScience, Josh Disbrow, Zertane, RedoxSYS, ProstaScint

Aytu to acquire rights to Jazz Pharmaceuticals’ ProstaScint prostate detection drug

Aytu to acquire rights to Jazz Pharmaceuticals’ ProstaScint prostate detection drug

ENGLEWOOD-- Aytu BioScience Inc. (OTCMKTS: RSWN), a specialty health care company focused on developing treatments for urological and related conditions, today announced it entered into an... Read More

By: InnovatioNews Tuesday June 9, 2015 0 comments Tags: Englewood, Aytu BioScience, Jazz Pharmaceuticals, Josh Disbrow, ProstaScint, Zertane, RedoxSYS

Ampio subsidiary Luoxis Diagnostics expands research network to more than 25 sites around world

Ampio subsidiary Luoxis Diagnostics expands research network to more than 25 sites around world

ENGLEWOOD - Ampio Pharmaceuticals Inc. (NYSE MKT: AMPE) today announced its subsidiary - Luoxis Diagnostics - has expanded its academic and pharmaceutical research network to more than 25... Read More

By: InnovatioNews Monday August 11, 2014 0 comments Tags: Englewood, Josh Disbrow, Luoxis Diagnostics, ORP, RedoxSYS